This proposal is a prospective study in which we will collect both subjective and objective quantitative data from older adults residing in independent living retirement communities, microlongitudinally (~1wk). Comprehensive measures of sleep health, cognition, and movement will be collected at community residences. The first phase of this project will recruit local, State College area adults over 70 residing in independent living facilities (e.g., Foxdale Village and The Village at Penn State). A second phase of data collection will extend to community-based older adults in rural parts of Centre and nearby counties.With this prospective, microlongitudinal information we will evaluate the characteristics of sleep predictive of daytime cognitive and neurobehavioral function and use those conclusions to inform nonpharmacologic, preventative interventions for older adults.

After consent, there will be 6 study visits at either Penn State University Park campus or at the participant's personal residence. Study participation lasts about 1 week.Participants wear non-invasive ambulatory watch-like activity monitors throughout (both day and night) the week. Participants complete electronic surveys and cognitive tests 6 times daily, with additional surveys at study conclusion.Sleep and daytime brain and heart activity are recorded (without video) using non-invasive clinical-type wire sensors applied to the face, head, and chest. Wires are worn on the face, head, and chest throughout the first two study nights. Wires are worn on the head and chest throughout the first two study days. There is not a sleep intervention in this study. We are collecting data about the typical sleep health of older adults and its relation to cognitive health.

$350

The objective of this protocol is to study urothelial cancer with detailed health history, tumor and/or normal tissues available for genomic sequencing to study cancers in the bladder, upper urinary tract, and urethra. There will be 3 groups of subjects in this study:1)Urothelial cancer patients receiving care at Penn State Health2)Relatives of patients with urothelial cancer3)High risk-cohort of individuals with family history of urothelial cancers or inherited cancer syndromes (such as Lynch syndrome) candidates for urothelial cancer screening evaluation

All subjects will be asked to fill out questionnaires to assess risk factors for urinary cancer and document family history of cancer. You will be asked to provide a blood sample and urine sample for genetic testing. Patients with urothelial cancer will be asked to allow us to test leftover tissue from a past or future biopsy to test cancer and/or normal cells for certain mutations. We may also ask you for a saliva sample, cheek swab, skin biopsy, or nail clippings for comparison.

The purpose of this study is to find out if the experimental drug (brensocatib) improves symptoms of Chronic Rhinosinusitis Without Nasal Polyps and is safe. Study treatments include the study drug and mometasone furoate nasal spray (referred to as mometasone). The study drug will either be brensocatib (“active” drug that contains “real” drug) or placebo (looks like brensocatib but does not have any “real” drug in it). Mometasone will be taken by all participants throughout the study as routine care.

If you choose to participate in the study, the following main activities and procedures are required.•Complete questionnaires asking about your chronic rhinosinusitis symptoms and quality of life•Measure the amount of air you can breathe in through both sides of your nose (nasal airflow)•Electrocardiogram (ECG) and vital signs•Physical examination, including examinations of your mouth and skin•Provide blood and urine samples•Sinus computed tomography (CT) scan•Attend 9 study visits•Nasal endoscopy

Unknown at this time

The goal of this pilot study is to collect preliminary information about the effectiveness of a smoking cessation app called quitSTART, which is a product of Smokefree.gov created by the Tobacco Control Research Branch at the National Cancer Institute. The app is available to the public for download at no cost. The aims of the project are: 1) to measure how participants respond to the app and how they use it during an attempt to quit smoking; and 2) receptivity and adherence rates to the app; 2) to examine whether participants reduce or discontinue smoking while using the app.

The study is designed to test the efficacy of a smoking cessation smartphone app and has three parts. For the first part, participants are asked to watch an orientation video about the study, fill out questionnaires, and watch a video tutorial explaining how to use a smartphone app. Then, for the second part of the study, participants are asked to use the smoking cessation app to help them with their quit attempt for 30 days. Finally, for the third part of the study, participants are asked to complete an exit survey about their experience using the app after 30 days.

$20

The purpose of this voluntary research study is to test the effects of exercise on reduction in blood flow to exercising muscle.

You will be asked to participate in one visit to perform handgrip exercise and foot exercises with, and without a blood pressure cuff inflated on your arm and leg. Various physiological measurements will be recorded during this time including microneurography, blood pressure, heart rate, blood flow and muscle oxygenation.

You will receive $25 per hour for your participation in this research study

This study is being done to learn if a vaccine made in the laboratory from your tumor and your immune cells is safe to give to you to treat your tumor. It is believed that the body’s immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to kill the tumor. In this research study, we will use your tumor and immune cells from your blood to make a vaccine that we hope will stimulate your T-cells to kill tumor cells and leave your normal cells alone.

You will need routine (standard of care) testing for your tumor, as well as research tests and procedures including further analysis of your tumor sample, generation and review of a personalized genetic report, and procedures to collect certain cells for different infusions and creation of specialized cellular vaccines. You will then be offered and placed on a treatment plan. As a subject in this study you will remain in this study until you complete vaccine therapy as long as you have no disease progression or unless you need to come off study for another reason.

This is a voluntary research study that will help us see if the study medication, CSL312, is safe to use in children 2-11 years of age. The research study will also help to see if the medication works to prevent HAE attacks in this age group.

Attend 8 to 9 visits to the study center. Provide personal information about the child participating in the study and complete electronic diaries (eDiaries). The child participating in the study will have physical exams, vital signs, and blood/urine tests completed. The study medication will be given via injection.

This study uses a baseline assessment and 28 days of ecological momentary assessment to examine the association of emotion dynamics to craving and alcohol use among people in the first year of cessation of heavy drinking and remission from DSM-5 AUD.

There will be one in person visit. Participants will be asked to complete baseline questionnaires. After the baseline assessment, participants will complete 28 days of daily diary questions on their cell phone. A prompt will be sent to the phone 3 times per day. It should take 5 minutes (15 minutes total/day) to complete the questions.

189

The purpose of this study is to investigate whether fermenting pulse foods (e.g. beans, chickpeas, lentils, peas, etc.) changes their effects on the gut microbiome and inflammation. Participants will eat provided meals of either fermented or unfermented pulses, providing blood and fecal samples at the beginning of the study and after two weeks of eating meals containing each of the pulse types.

The study lasts 8 weeks. 2 weeks where you do not consume any of the test food (pulses such as chickpeas, lentils, peas or beans), 2 weeks of consuming the first type of the provided meals, 2 weeks without consuming any of the test foods, 2 weeks consuming the second type of provided meals. There will be five in person visits, one at the beginning to provide consent and then one at the end of each 2 week section. At three of these visits a fecal sample will be collected, blood will be drawn and a dietary survey completed.

300

To comprehensively examine the psychological effects of abstract lighting patterns on individuals' emotional states, cognitive performance, and overall well-being. Secondly, the study aims to explore the intriguing connection between music-color synesthesia and the perception of lighting conditions.

Participants will complete cognitive tests and subjective evaluations

The purpose of this study is to test how social decisions are affected by possible risk of infection. We aim to examine the neural and behavioral mechanisms underlying how choices in a risky social decision-making situation can be influenced by viewing images of infection threat (e.g., person with runny nose) vs. images of neutral scenes or other threatening scenes.

Participants will come to the research site for a one-time visit. They will complete brief questionnaires, followed by playing a social decision-making game while undergoing fMRI scanning.

$35.42

The effect of familiarity of an space on visual and lighting perceptions, and the effect of lighting conditions on risk taking and decision making will be investigated

Participants will wear sensors and complete survey that consists of decision making questions and subjective evaluations of architectural spaces.

This trial will be looking at patients with OncoSignature positive and negative tumors using the treatment of the study drug in combination with ultra low dose gemcitabine.

If you are in Arm 1, you will receive ACR-368 as a single intravenous (in the vein) infusion over approximately 60 minutes twice during a 4-week period, on Days 1 and 15. This entire 4-week period is called a cycle. If you are in Arm 2, you will receive gemcitabine and ACR-368 as two separate intravenous (in the vein) infusions. The gemcitabine infusion will last approximately 30 minutes and the ACR-368 infusion will last approximately 60 minutes. •Biopsy Sample and OncoSignature® Status•Archived Tumor Sample and Genomic Information•Physical Exam•Pregnancy Test if applicable•Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan•Blood Sampling for CA-125 (Ovarian carcinoma only)

In this study, we hope to better understand the neural mechanisms underlying risk for personality disorders in adolescent youth. Understanding who is at risk for personality disorders early in development is important in order to develop preventative interventions.

Youth participants and their parent will be required to attend one in-person visit at our lab in Hershey, PA where youth participants will complete two computer tasks while EEG data are collected. Youth participants will also complete questionnaires and a peer-interaction task with another peer their age. Parents will complete questionnaires and an interaction task with their child. Youth participants will complete remote surveys via a survey app for two weeks after the visit. This study includes 4 follow-up appointments (once every 6 months) which can be completed in-person or remotely via a Microsoft Teams meeting. These follow-up appointments will consist of a parent-child interaction task and surveys for parent and youth participants.

$300

The objectives of the study are to determine whether grip force is related to participants’ fear and whether touch feedback from a robot can effectively communicate risk in a simulated high stress environment. We hypothesize that grip force increases in stressful situations like walking through a haunted house. Like in a real haunted house, people often find comfort in holding hands with someone as they walk through. In this study, a participant walks through a virtual haunted house.

There will be one in person visit. Participant will wear VR equipment and chest heart rate monitor. They will hold a virtual robot's hand and walk through a VR haunted house environment until it is over. They will then answer a brief survey.

15

In this study, we're investigating how the COVID-19 pandemic has influenced the way people who face challenges in transportation—perhaps due to limited access or resources—get around. We're curious about any changes they made during the pandemic, like using different modes of transportation or adjusting their travel habits. Additionally, we're exploring whether these changes might stick around even after the pandemic. It's all about understanding the impact of the pandemic on the travel choices of those who already face transportation difficulties and what this might mean for the future.

There will be a questionnaire that should take approximately 15 minutes to complete.

This study will be a pilot study to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously confirmed in patients with cirrhosis,(1) in patients with Nonalcoholic Steatohepatitis (NASH)

El-Fit NASH (Nonalcoholic Steatohepatitis) is a 9-week intervention trial for patients with NASH. Our goal is to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program. The El-FIT application allows for participants to access to a library of guided workouts. All patients will be asked to complete a screening visit that includes a physical exam, height, and weight measurements & surveys. Participants will be asked to download the EL-Fit NASH application and use it for 8 weeks. In addition to using the application, participants will be asked to complete 3 check-in phone calls through-out the 8 weeks.

The purpose of this study is to collect normative data related to orofacial (lip/tongue) somatosensation (touch sensation) in healthy adults across the adult lifespan. This data will be compared to a select clinical population, those with Parkinson's disease.

There will be one data collection session lasting approximately 90 minutes. Participants may be invited back for a second session approximately 4 weeks later to repeat the testing sessionDuring the sessions, participants will answer a series of questions about their eating and drinking preferences, they will be asked to provide a speech sample by repeating a series of syllables, words, and sentences, as well as providing a spontaneous speech sample.All participants will be asked to complete a series of sensory tests where small plastic objects are placed on their lip, tongue, and finger tip. Participants will be asked when they feel the pressure/texture and when they do not.

Hepatic encephalopathy (HE) is a complication of liver cirrhosis (liver damage). It affects nearly half of people with cirrhosis. Because of the damage, the liver doesn’t work as well as it should, and some toxins stay in the body. HE occurs when too many toxins build up in the bloodstream and reach the brain. It can cause symptoms like confusion, personality changes, lack of energy, inappropriate behavior, sleep problems, loss of small hand movements and tremors in hands and arms.This study is looking to see if a study medicine, rifaximin, can safely delay or prevent HE. Adults who have been diagnosed with liver cirrhosis, but who don’t have yet HE may be eligible to join.•Participants will be in the study will up to 80 weeks. They will attend up to 21 study visits, including 14 visits to the clinic and 7 telephone check-ins.•If participants are eligible and choose to participate, they will be randomly (like a flip of a coin) assigned to one of two treatment groups: the study medicine or placebo (which contains no active ingredients). This means participants have a 50/50 chance of receiving the study medicine.•Both study groups will take their assigned study medicine study medicine as a pill twice a day.•The study is double-blind, which means neither the participant nor the study team will know which treatment they are receiving.

There will be 14 in person visits. Safety assessments will be done at each visit including blood tests and urine tests. Participants will need to take study drug as directed.

$1050.00

The purpose of this research study is to determine if a healthy diet containing 2 eggs/day has similar effects on risk factors for heart disease as a healthy diet containing 3 eggs/week.

This study runs for about 3 months. During this time, you will be provided with two diets in random order to consume for 28 days. These diets will meet your energy and nutrient needs and include 3 meals, 2 snacks and some beverages. During this time, we will ask you not to eat any foods outside of those provided by the study. You will have a 1-month break between the two diets. Testing will be conducted on two separate days at the beginning and end of each diet period (a total of 8 testing days). For these visits, you will need to fast for 12 hours prior and avoid alcohol for 48 hours prior. At these visits, we will take a blood draw, measure your body weight, and perform non-invasive tests to assess your vascular health.

400

The aim of this study is to examine the effect of wearing CROCS with or without a heel-strap on walking mechanics.

There will be one in-person visit to take place at Penn State Altoona. During this visit, lasting approximately two hours, participants will undergo a simple consent process and they will provide information about their physical activity and fitness history. Body measurements, such as height, weight, and leg length will be recorded during the visit. Participants in the study will complete a five-minute treadmill warm-up at a self-selected walking speed while wearing a pair of CROCS, Inc. clog-style shoes (provided). After the warm-up participants will complete a series of 15 walking trials consisting of three randomized conditions (barefoot, no heel-strap, heel-strap) on a level and firm walking surface. During these trials, the participant will wear lightweight sensors on the lower-body to track walking patterns. Images and videos will be acquired during the visit, but all distinguishing features will be blurred or omitted upon archiving.

Phase 3, global, randomized, double-blind, placebo-controlled, multi-center study that will evaluate upadacitinib in the treatment of moderate to severe HS in adult and adolescent subjects who have failed to respond to or are intolerant of ant-TNF therapy and/or 1 approved non-anti-TNF-biologic therapy for HS.This study is comprised of a 35-day screening period, a 16 week placebo-controlled, double-blinded treatment period (Period 1), a 20-week re-randomized extension treatment period (Period 2), a 68-week long-term extension treatment period (Period 3) and a 30-day follow-up period.

You will completed 3 study periods over approximately 104 weeks. During that time at different time points you will have your skin examined, ECG, complete questionnaires, and have your labs drawn. In addition you will take the study medication as directed by the research study coordinators.

This study will compare the use of CCT-102 with expectant management to promote uterine evacuation in first trimester non-progressing Delayed Pregnancy Loss (DPL). Eligible participants will be randomly assigned to active treatment or expectant management and will undergo ultrasound, physical examination, sample collection and complete daily diaries.for six days. Participants will be monitored up to 208 days until a negative urine hCG test is achieved.

There are 3 visits and a screening visit which may be combined with visit 1. A physical examination, ultrasound and blood draw will take place at screening and visit 2. Urine pregnancy tests will be taken at screening, visit 1, visit 2 and at home on days 14, 21 and 28 or until a negative result occurs. Electronic diaries will be logged days 1 through 7

595

The purpose of this study is to assess if a healthy diet containing cottonseed oil improves markers of heart and metabolic health compared to healthy diets containing other commonly consumed plant oils. Participants will be asked to consume three different healthy diets containing plant oils for 28 days each, with a minimum 1-month break between the three diets. Measurements of blood markers (sugar, insulin, cholesterol), blood pressure, and heart health, will be done at the start of the study and the end of each diet period.

In this study, you will be asked to consume three different diets for 28 days each. The diets will be provided and include 3 meals, 2 snacks and beverages daily. These diets will meet your energy and nutrient needs. You will be asked not to eat any foods outside of what is provided by the study. You will have a minimum 1-month break between the three diets. Testing will be conducted on two consecutive days at the start of the study, and the end of each of the three diet periods (a total of 8 testing days). For these visits, you will need to fast for 12 hours prior and avoid alcohol for 48 hours prior. At these visits, we will take a blood draw, measure your body weight, and perform non-invasive tests to assess your vascular health.

500

This research experimental study aims to investigate the impact of gender and language on stigma related to opioid use disorder (OUD) among college students. Participants, aged 18 and older, will be randomly assigned to read vignettes describing individuals with OUD, varying in gender and language use. After reading, participants will complete a brief survey assessing their perceptions of stigma associated with OUD. The study seeks to uncover how stigmatizing language and gender-specific societal expectations interact to shape attitudes, contributing to a better understanding of OUD stigma in the college-aged population.

Participants will engage in a structured series of activities. Initially, they will complete a demographics questionnaire, providing essential information such as age, gender, and college affiliation. Subsequently, participants will be presented with one of four vignettes designed to systematically manipulate language and gender variables related to OUD stigma. Following the vignette exposure, participants will respond to The Perceived Stigma of Substance Abuse Scale (PSSAS) as part of the survey.

This one-time survey seeks to understand both patient and provider perspectives of and preferences for a predictive test for side effects among breast cancer patients treated with an aromatase inhibitor (AI).

Complete a one-time electronic survey asking for opinions on a predictive test for side effects of aromatase inhibitor (AI) breast cancer treatments.

The purpose of this study is to define how eye movements contribute to eye-hand coordination in individuals of the age group 18-50 (young adults) and 65-80 (older adults). Specifically, the aim of the study is to understand how slow eye movements affect arm and hand movements. All procedures to be used in our study will be non-invasive. The task during the study will be performed with a robotic handle that participants will grasp with their right hand. They will interact with visual stimuli by moving the robotic handle. The robotic environmentwill attempt to simulate real-world mechanical interactions, such as those experienced during catching a ball.

During this study, we will ask you to come to our laboratory located in 23 Recreation Building,Pennsylvania State University, on two days separated by a maximum of 48 hours. Both sessions will last approximately 90-120 minutes. During the first session, we will review the procedures with you and if you agree to participate, you will sign this form and then proceed to perform the study. You will perform about 20-25 blocks of hand movements. Each block will consist of 24-30 trials and each trial will last between 3-5 seconds.The second day will be identical to the first day but the order of trials within a block will be changed.

$10/hour

Determine if free radicals produced by electronic cigarettes or conventional cigarettes impact inflammation and oxidative stress responses in users.

Subjects will come to the Clinical Research Center at Hershey and if they are a nicotine user they will bring their device (cigarette or e-cigarette) with them. Healthy volunteers will answer the same questionnaires and provide the same samples but will not use any nicotine during their visit. They will provide blood, urine and exhaled breath condensate samples. They will be videotaped using their own devices and they will answer questionnaires. This is a one-time visit that will last around 2 hours.

50

This study is designed to better understand how people complete complicated tasks, and the best ways in which to measure their performance. If you agree to the study, you will be asked to fill out questionnaires on your thoughts, feelings, and behaviors; take a short interview on the same; and complete brain teasers and computerized tests of attention and learning.

There are several steps to determining whether you are a good fit for the study. If you agree to be in the study, then we will send you a link to complete online questionnaires (~10 min) on your thoughts, feelings, and behaviors. If you are a good fit, then we will schedule a laboratory visit in Moore Building at the University Park campus (maximum length of time = 3 hours). During that visit you will complete an interview and more questionnaires, brain teasers, and computerized tests of attention and learning. The visit will be video recorded for quality assurance.

$50

This is a Phase 2, multicenter, double-blind, randomized, 52-week study to assess the efficacy and safety of K-001 medication compared with placebo in subjects with noncirrhotic NASH with liver fibrosis. This study will look at a study drug, called K-001, for participants with a liver condition called noncirrhotic nonalcoholic steatohepatitis (NASH). This condition is defined by a build-up of fat in the liver, which causes liver damage and inflammation. Due to this damage, the liver does not work as well. If left untreated, NASH can lead to liver fibrosis (scarring of the liver), liver cancer, or liver failure. K-001 is a once daily pill that contains combination of two medicines: K-877-ER and CSG452. The purpose of the study is to find out whether the study drug works and how safe it is in participants diagnosed with NASH with liver fibrosis. To answer these questions, the study drug will be compared with a placebo.

There will be 10 in person visits over 52-week study period. Various procedures will be completed such as a fibroscan, ECG, liver MRI, liver biopsy, blood draws. You will be randomly assigned by chance (like the flip of a coin) to receive the study drugs or placebo (inactive substance). You will be taking a pill once daily.

$1310